2025-521462-96-00招募中1 期
A Phase 1b, Open-Label Study of CLN-978 for the Treatment of Active, Moderate to Severe Sjogren’s Disease
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 10
- 试验地点
- 6
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Study Responsible Physician
Scientific
Cullinan Therapeutics Inc.
研究点 (6)
Loading locations...
相似试验
招募中
2 期
An open-label, phase I/II study of T3P-Y058-739, a genetically-modified strain of the bacterium Yersinia enterocolitica, in patients with advanced solid tumours2023-504199-19-00T3 Pharmaceuticals AG40
已完成
1 期
A Trial to Determine the Safety of CC-93269, an Antibody, in People who have Multiple Myeloma That Has Returned After a Period of Treatment And is not Responsive After Treatment.2023-506564-14-00Celgene International II S.a.r.l.112
招募中
1 期
A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)2024-512089-32-00ADC Therapeutics SA121
招募中
1 期
A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-Tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients with Selected Advanced Cancers. Catherine Trial2024-516660-28-01Vall D Hebron Institute Of Oncology15
招募中
1 期
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications2023-506227-29-00AbbVie Deutschland GmbH & Co. KG60